Additionally, the company has the largest portfolio of muscarinic compounds in clinical development, including NBI-‘568 for ...

Since a schizophrenia drug, the first in decades with an innovative mechanism of action, gained US regulatory approval in ...

2009年，Karuna ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

Many people have cats in their lives and enjoy sharing most of their comforts with them, including our food. Cats are ...

Vanderbilt University has described muscarinic M4 receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, sleep disorders ...

RVPH READ THE FULL RVPH RESEARCH REPORT Operational and Financial Results On November 14th, 2024, Reviva Pharmaceutical ...

Anavex Life Sciences (AVXL) stock rises 10% in premarket as company submits EU marketing application for Alzheimer's drug ...

Emraclidine was expected to be a competitor to Bristol Myers Squibb’s recently approved Cobenfy, but trial results put its ...

a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate ...

First marketing authorization submission for blarcamesineNEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or ...

Verona's approval of ensifentrine in COPD offers promising potential with its MoA and safety profile in a competitive market.